Xylometazoline 0.1% Adult Nasal Spray

Xylometazoline 0.1% Adult Nasal Spray belongs to the Nasal Sprays category within the Cough & Cold and Respiratory therapeutic segments. Xylometazoline is an imidazoline-class alpha-adrenergic agonist — the same pharmacological class as naphazoline and oxymetazoline — but is distinguished by its unique combination of alpha-1 and alpha-2 receptor affinity that delivers both rapid onset (1–3 minutes) and prolonged action (8–12 hours) from a single nasal application.

The 0.1% adult concentration is the standard prescribing strength for patients above 12 years, providing the full therapeutic dose of Xylometazoline per actuation to achieve complete nasal decongestion from a twice-daily dosing regimen — a meaningful compliance advantage over shorter-acting decongestants requiring three to four doses per day.

Xylometazoline nasal spray is a consistently high-prescription, high-volume product in the Indian ENT and cold care market with year-round demand driven by allergic rhinitis and strong seasonal peaks during winter cold and spring allergy periods. For pharmaceutical marketing companies building ENT or respiratory portfolios, this is a foundational SKU with excellent prescription velocity and retail pharmacy movement. Saar Biotech manufactures it from our facility in Baddi with specialized nasal spray filling infrastructure.

Manufacturing a nasal spray correctly requires significantly more technical precision than standard oral liquid manufacturing — from pump actuation calibration to preservative efficacy and mucosal pH compatibility. Saar Biotech’s dedicated nasal spray manufacturing infrastructure addresses each of these requirements:

• Metered-Dose Pump Calibration: Every batch undergoes spray dose uniformity testing confirming the metered pump delivers a consistent dose volume per actuation from first spray to the last usable dose in the 10ml bottle. Inconsistent actuation is the most common quality failure in nasal spray manufacturing and can cause dose variability that undermines brand clinical performance.
• pH and Tonicity Optimization: Xylometazoline nasal solutions must be pH-buffered and isotonically adjusted to prevent mucosal irritation, stinging, and discomfort on application. Our formulation maintains the solution within the physiological nasal pH range and osmolarity that ensures patient comfort and mucosal safety with regular use.
• Preservative System Validation: The Benzalkonium Chloride preservative system is validated for antimicrobial efficacy throughout the product’s multi-dose use period per IP/Ph. Eur. preservative efficacy testing requirements.
• Metallic Carton Premium Capability: The metallic carton + metallic sticker label presentation for the 10ml Xylometazoline format creates a premium brand identity at ENT specialty and pharmacy counter level — Saar Biotech’s full metallic packaging capability allows B2B partners to compete in the premium nasal spray segment.

Xylometazoline 0.1% Adult Nasal Spray is manufactured and supplied by Saar Biotech for the following clinically established indications in adults and adolescents above 12 years:

• Nasal Congestion — Common Cold: Rapid decongestion of blocked nasal passages from viral upper respiratory infections, providing 8–12 hours of breathing relief per application.
• Allergic Rhinitis: Relief of acute nasal congestion episodes in seasonal and perennial allergic rhinitis, used as a short-term bridge while allergen exposure is managed.
• Sinusitis & Rhinosinusitis: Adjunctive decongestant therapy to reduce nasal mucosal swelling, facilitating sinus drainage and improving mucociliary clearance in acute sinusitis.
• Eustachian Tube Congestion in Otitis Media: ENT practitioners use Xylometazoline to relieve eustachian tube mucosal swelling in otitis media, reducing ear pressure symptoms.
• Pre-Procedural Nasal Preparation: Applied before nasal examinations, rhinoscopy, or minor ENT procedures to shrink mucosa and improve visualization.

Schedule H — Requires valid medical prescription. Maximum continuous use: 3–5 days. Not for children under 12 years.

Clinical Mechanism — Alpha-Adrenergic Vasoconstriction

Xylometazoline belongs to the imidazoline class of sympathomimetic agents. It acts directly on alpha-1 adrenergic receptors located on arterial vascular smooth muscle cells in the nasal submucosal sinusoids (capacitance vessels) — causing rapid, intense vasoconstriction that reduces sinusoidal blood volume and the resulting mucosal edema. Simultaneously, its alpha-2 agonism on presynaptic receptors reduces noradrenaline release from sympathetic nerve terminals, contributing to the sustained duration of vasoconstriction beyond that achievable with pure alpha-1 agonists.

The onset of action is exceptionally rapid — mucosal decongestion typically begins within 1–3 minutes of application — making Xylometazoline one of the fastest-acting nasal decongestants in clinical use. The prolonged 8–12 hour effect enables twice-daily dosing, which is a significant patient compliance advantage over shorter-acting decongestants.

Manufacturing Integrity

• Chemical Stability of Xylometazoline HCl: Xylometazoline is sensitive to oxidation in alkaline aqueous environments. Our formulation uses disodium EDTA as a chelating agent to sequester metal ions that catalyze oxidation, and the solution pH is maintained in a mildly acidic range that maximizes chemical stability across the 24-month shelf life.
• Pump Seal Integrity: Nasal spray pumps must maintain a complete seal that prevents oxidation of the Xylometazoline solution through air ingress and prevents microbial contamination between uses. Our pump assemblies are validated for seal integrity across the expected actuation lifecycle.

• Rapid Onset, Prolonged Action: The 1–3 minute onset combined with 8–12 hour duration creates a compelling clinical narrative for prescribers — one spray in the morning and one at bedtime provides around-the-clock nasal decongestion during the acute cold or allergy period. This convenient dosing schedule is a direct commercial asset for brand field promotion.
• Minimal Systemic Absorption: When used correctly (one to two sprays per nostril, twice daily), Xylometazoline 0.1% produces minimal systemic absorption from the nasal mucosa. Plasma concentrations remain well below pharmacologically significant thresholds for cardiovascular effects — the therapeutic action is entirely local. This safety profile is important for B2B brand positioning in a Schedule H environment where physicians seek reassurance about cardiovascular safety in patients with hypertension or cardiac risk.
• 3–5 Day Use Protocol as a Commercial Feature: The strict maximum use duration creates a predictable, defined treatment course — each 10ml bottle is purchased for one cold or allergy episode. This episode-based repeat-purchase pattern drives consistent pharmacy offtake through cold and allergy seasons, supporting strong retail rotation metrics for ENT brands.
• Premium Metallic Carton Brand Positioning: In the nasal spray segment, premium metallic packaging significantly differentiates a brand from generic economy presentations at pharmacy counters, where visual impact influences pharmacist recommendation and patient pick-up.

Saar Biotech provides Contract Manufacturing (CMO) and Third-Party Manufacturing for Xylometazoline 0.1% Adult Nasal Spray from our nasal spray manufacturing facility in Baddi, Himachal Pradesh.

• Facility: Specialized nasal spray filling line with metered-dose pump assembly, automated filling, crimping, and secondary packaging for 10ml presentations.
• Capacity: From 5,000-unit brand-entry batches to 1,00,000+ unit commercial seasonal runs; shrink configurations available for pharmacy display multi-packs.
• Quality Lab: In-house GLP-certified lab with HPLC for Xylometazoline and BKC assay, spray dose uniformity testing, pH, osmolarity, MLT, and preservative efficacy testing.
• Turnaround: New orders — 30 to 45 working days. Repeat orders — 20 to 25 working days.
• Packaging: 10ml metered-dose pump spray bottle; with carton, metallic carton + metallic sticker, drip-off embossed carton, shrink pack; Schedule H compliant labeling on all presentations.
• MOQ: 5,000–10,000 units per SKU.

1. Store Below 30°C: Xylometazoline is susceptible to oxidative degradation at elevated temperatures. Distribution and pharmacy storage must avoid sustained heat exposure above 35°C, particularly relevant for summer supply chain management.
2. No Freezing: The aqueous nasal solution must not be frozen. Freeze-thaw cycling can compromise the pump valve seal and alter the solution’s preservative distribution.
3. Upright Storage: Nasal spray bottles should be stored and transported upright to maintain the pump mechanism’s prime and prevent solution from pooling around the valve, which can cause inconsistent first-spray delivery.
4. In-Use Duration: Patients should use the bottle within 30 days of first opening, not exceed 3–5 consecutive days of continuous use, and keep the nozzle cap in place when not in use.

Every batch of Xylometazoline 0.1% Nasal Spray is released from our GLP-certified QC laboratories in Baddi only after completing the following testing protocol:

• HPLC Assay (Xylometazoline HCl): Confirmed at 0.1% w/v against IP specification — the primary potency release test.
• BKC Preservative Assay: Benzalkonium Chloride confirmed at 0.01% w/v — critical for multi-dose bottle microbiological safety.
• pH Verification: Solution pH confirmed within the nasal-compatible, stability-optimal range.
• Spray Dose Uniformity: Actuation dose volume confirmed within tolerance across the life of the bottle.
• Microbial Limit Testing (MLT): Nasal solution product-appropriate pathogen absence confirmation per IP.
• Fill Volume Accuracy: Confirmed per specification for the 10ml bottle.
• Certificate of Analysis (COA): Issued with every B2B batch consignment.

Xylometazoline 0.1% is generally well tolerated within the recommended 3–5 day use period. Common local effects include mild transient burning or stinging on application, sneezing, and increased nasal secretions immediately following use. With prolonged use beyond the recommended duration, rhinitis medicamentosa (rebound congestion) is the primary adverse effect — patients become dependent on the spray to maintain nasal patency. Systemic effects from nasal absorption at standard doses are uncommon but include mild cardiovascular stimulation (elevated blood pressure, palpitations) in sensitive individuals.

Contraindicated in angle-closure glaucoma, dry rhinitis, and MAO inhibitor use. Use with great caution in severe cardiovascular disease and hypertension. Not for use in children under 12 years — use the 0.05% pediatric formulation for younger patients.

For third-party manufacturing enquiries, private-label contracts, or to request pricing and packaging options for Xylometazoline 0.1% Adult Nasal Spray, please use the B2B enquiry form below.